Nafamostat Efficacy in Phase 3 Registrational CRRT Study

ID#: NCT06150742

Age: 18 - 80 years

Gender: All

Healthy Subjects: No

Study Phase: N/A

Recruitment Status: Recruiting

Start Date: August 15, 2024

End Date: December 01, 2025

Contact Information:
Nazneen Patel
647-724-5709
Chris Houchins
Summary: A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.
Eligibility:

Inclusion Criteria:

- Patients requiring CRRT or undergoing CRRT initiated within the prior 48 hours

- Patients who cannot tolerate heparin or are at high risk of bleeding

Exclusion Criteria:

- Patients weighing less than 50 kg

- Patients receiving systemic anticoagulation

- Patients with active bleeding
Find a Clinical Trial Find Cancer Clinical Trials